AlphAIAlphAI — Financial news for AI agents
investing.comOCT 52 min read$KYMR

Citi raises Kymera Therapeutics stock price target on drug potential

Citi raised its price target for Kymera Therapeutics (KYMR) to $150 from $135, citing potential for its KT-621 drug in atopic dermatitis. The stock is up 85% over the past year. Citi expects $2.5B in peak sales by 2032. Other analysts also raised targets, with estimates ranging from $111 to $180.

Original reporting
investing.com
Published Oct 5, 2026, 9:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 10:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$KYMR
Bullish
high confidence
Mentioned
$KYMR
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KYMRBullishMed
01

Why it matters

Analyst upgrades increase visibility and may drive short‑term buying, but the stock remains high‑risk due to trial uncertainty.

02

Market read

The new target could spark buying interest ahead of the Phase 2b readout, affecting KYMR and potentially related biotech peers.

03

What to watch

Potential regulatory delays, competition from Dupixent, and the high beta of KYMR could amplify downside risk.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

Kymera Therapeutics is developing an oral STAT6 degrader (KT‑621) for atopic dermatitis, with Phase 2b data expected year‑end 2026.

Company-level read

Ticker impact

$KYMRBullishHigh confidence
Context

Citi raised its price target on Kymera Therapeutics to $150 from $135 and maintained a Buy rating.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

Citi's new target reflects confidence in upcoming Phase 2b data and market share potential, which can attract buying interest.

Market effects

Sector

Boosts sentiment for the broader biotech/rare‑disease sector as analysts highlight trial progress.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minor global impact; primarily influences U.S. and European biotech portfolios.

Counterpoint

What could challenge this read

If Phase 2b data disappoints, the higher target may be premature and could lead to a sharp correction.

Key entities

  • company
    Kymera Therapeutics

    Biotech firm developing oral STAT6 degrader for atopic dermatitis.

  • analyst
    Citi

    Investment bank that raised the price target to $150.

Read at source← All news

Related articles

OCT 8
$KYMRMed

Raymond James initiates Kymera Therapeutics stock coverage with outperform rating

Raymond James initiated coverage on Kymera Therapeutics (KYMR) with an Outperform rating and $140 price target, citing its drug pipeline and upcoming trial results. The stock has gained 94% over the past year but may be overvalued. Analysts maintain a bullish stance with targets ranging from $111 to $180. Recent updates from Citi, B.Riley, and Piper Sandler also highlight the company's potential.

investing.com2 min
SEP 10
$KYMRMedAI 8/10

Kymera Therapeutics at citigroup summit: oral immunology push gains pace

Kymera Therapeutics (KYMR) presented its focus on oral immunology at Citigroup's Biopharma Summit, highlighting STAT6 and IRF5 programs. STAT6 aims to treat type 2 inflammation, with Phase III readout expected by year-end 2024. IRF5 targets autoimmune diseases, with human genetics and biological validation. The company seeks to become an independent commercial entity, focusing on immunology. Kymera's stock is up 2.54% to $118.36.

investing.com2 min
SEP 1
$KYMRMedAI 8/10

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Kymera Therapeutics (KYMR) announced presentations on KT-621, its oral STAT6 degrader, at ERS and EADV congresses. The company completed enrollment in the BROADEN2 Phase 2b trial for atopic dermatitis, with topline data expected by year-end 2026. Phase 3 trials are planned for mid-2027. The BREADTH Phase 2b asthma trial is ongoing, with data expected in late 2027.

investingnews.com2 min
AUG 12
$KYMRMed

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics (KYMR) reported Q2 2026 collaboration revenue of $65M, including a $45M Gilead option fee and $20M Sanofi milestone. Cash and investments were $1.5B as of June 30, 2026, runway into 2029. R&D rose to $119.5M. KT-621 AD Phase 3 initiation is mid-2027, and asthma data is late 2027.

fool.com7 min
AUG 6
$KYMRMed

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 results and updated its pipeline. Enrollment in KT-621 BROADEN2 Phase 2b atopic dermatitis finished nearly six months early, shifting topline data to year-end 2026 and Phase 3 start to mid-2027. KT-621 asthma data is due late 2027. KT-579 Phase 1 data is expected 4Q26. Cash was $1.5B as of June 30, 2026.

investingnews.com6 min